Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Brief Summary: The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.


Options:
A: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
B: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: Arm B: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Arm C: Nivolumab + Platinum doublet chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed, Drug: Paclitaxel | Arm Label: Arm D: Platinum doublet chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed, Drug: Paclitaxel | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab, Arm B: Nivolumab + Ipilimumab, Arm C: Nivolumab + Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy
C: Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine, Drug: cisplatin | Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm B
D: Arm Label: Pemetrexed/Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Bevacizumab | Arm Label: Pemetrexed/Bevacizumab/Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Bevacizumab, Drug: Carboplatin | Arm Label: Pemetrexed; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed, Pemetrexed/Bevacizumab, Pemetrexed/Bevacizumab/Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Pemetrexed/Bevacizumab, Pemetrexed/Bevacizumab/Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pemetrexed/Bevacizumab/Carboplatin

Answer: D